Log In
Print this Print this

Glyxambi, empagliflozin/linagliptin

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionCombination tablet of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and linagliptin, a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor
Molecular Target Sodium-glucose cotransporter 2 (SGLT2) ; Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
PartnerEli Lilly and Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today